Stay updated with breaking news from Ana Oaknin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adding atezolizumab to bevacizumab and platinum-based chemotherapy can improve outcomes in patients with metastatic, persistent, or recurrent cervical cancer, a phase 3 trial suggests. Adding atezolizumab to bevacizumab and platinum-based chemotherapy can improve outcomes in metastatic, persistent, or recurrent cervical cancer.
Adding atezolizumab to bevacizumab and platinum-based chemotherapy can improve outcomes in patients with metastatic, persistent, or recurrent cervical cancer, a phase 3 trial suggests. Adding atezolizumab to bevacizumab and platinum-based chemotherapy can improve outcomes in metastatic, persistent, or recurrent cervical cancer.
The addition of atezolizumab to bevacizumab and chemotherapy resulted in a significant improvement in progression-free survival and overall survival vs standard treatment with bevacizumab and chemotherapy in patients with metastatic, persistent, or recurrent cervical cancer.
Five-year survival odds improve and recurrence risk lowers when women receive induction chemotherapy before their standard treatment regimen.
Presented today by VHIO’s Ana Oaknin at the 2023 ASCO Annual Meeting, 2-6 June (Chicago, IL), updated dose expansion data of the STRO-002-GM1 global phase I study show promise of FolRα-targeting antibody drug conjugate (ADC) luveltamab tazevibulin in patients with recurrent FolRα-expressing epithelial ovarian cancer.